Biodegradable Intraocular Implant with High Prostamide Loading
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current eye drop treatments for glaucoma require frequent administration and often result in burst release of therapeutic agents, leading to ineffective long-term reduction of intraocular pressure, and existing intraocular implants face challenges in maximizing drug loading while minimizing size and side effects.
Innovation Solution
Development of biodegradable intraocular implants comprising a biodegradable polymer material and Compound 1, which are designed for extended release of a therapeutic agent directly to the ocular region, providing a controlled and sustained reduction in intraocular pressure by diffusing, eroding, or degrading within the eye.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If intraocular implants are designed to maximize drug loading, then the effective amount of drug delivered increases, but the implant size increases
Solution Approach 1:
The patent changes the chemical parameters of the polymer matrix by incorporating amino acid oligomers with specific sequences and properties. This allows optimization of drug-polymer interactions, solubility, and release kinetics to achieve high drug loading in a compact implant volume
Solution Approach 2:
The implant uses composite material construction combining biodegradable polymer matrix with amino acid oligomers. This composite structure enables simultaneous achievement of high drug loading capacity and controlled release kinetics while maintaining small implant dimensions suitable for ocular delivery
2Duration of action of moving object
If intraocular implants are designed for extended release, then the duration of action increases, but the initial drug release rate decreases
Solution Approach 1:
The patent employs dynamic release mechanisms where the polymer matrix progressively degrades and releases drug over time. The amino acid oligomers provide time-dependent release kinetics, enabling sustained delivery over extended periods while maintaining therapeutic drug levels
Solution Approach 2:
The implant design ensures continuous drug release through the progressive degradation of the biodegradable polymer matrix. This continuous action maintains therapeutic efficacy over extended periods without requiring repeated administrations
3Ease of operation
If intraocular implants are designed to reduce implant size, then the ease of administration increases, but the drug loading capacity decreases
Solution Approach 1:
By optimizing polymer molecular weight, composition, and amino acid oligomer parameters, the patent achieves high drug loading density in small implants. This allows easy intracameral or intravitreal injection while delivering sufficient therapeutic doses
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The implants achieve a prolonged and controlled release of the therapeutic agent, reducing intraocular pressure effectively for extended periods with minimal side effects, allowing for smaller implant sizes and reduced frequency of administration.
Implementation Method 1
a biodegradable polymer material and Compound 1
Implementation Method 2
biodegradable intraocular implants
Implementation Method 3
releasing a therapeutic agent, such as a hypotensive (or IOP-lowering) agent, at a sustained or controlled rate
Data Source
AI summary
Biodegradable intraocular implants with a high loading of a prostamide compound for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.